Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gunjan Shah

Showing results (21-30 of 53) with videos related to

Pageof 6
Sort By:
British Journal of Haematology|March 6, 2020
Early experience using salvage radiotherapy for relapsed/refractory non-Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T cell therapyBrandon S Imber, Michel Sadelain, Carl DeSelm, et al.
Transplantation and Cellular Therapy|October 3, 2023
Reduced-Intensity Compared to Nonmyeloablative Conditioning in Patients with Non-Hodgkin Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell TransplantationKarthik Nath, Kristen Peterson, Samantha Brown, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 18, 2025
Dermatologic Adverse Events Following CD19-Directed CAR T-Cell Therapy in Hematologic MalignanciesRyan Storgard, Rachel E Reingold, Rose Parisi, et al.
JACC. Cardiooncology|February 18, 2026
Atrial Fibrillation Following Autologous Stem Cell Transplantation in Multiple Myeloma: Incidence, Predictors, and Prognostic ImpactOlayiwola Bolaji, Samantha Brown, Brian C Shaffer, et al.
Haematologica|August 18, 2025
Two decades of single-institution data reveal rare long-term survivors of relapsed/refractory Burkitt lymphomaRabeya Molla, Kurt Bantilan, Ellin Berman, et al.
Haematologica|June 22, 2023
Predictors of SARS-CoV-2 Omicron breakthrough infection after receipt of AZD7442 (tixagevimab-cilgavimab) for pre-exposure prophylaxis among hematologic malignancy patientsJustin C Laracy, Judy Yan, Samantha N Steiger, et al.
Research Square|March 3, 2023
Bortezomib, Lenalidomide and Dexamethasone (VRd) vs Carfilzomib, Lenalidomide and Dexamethasone (KRd) as Induction Therapy in Newly Diagnosed Multiple MyelomaCarlyn Rose Tan, Andriy Derkach, David Nemirovsky, et al.
Leukemia & Lymphoma|September 10, 2023
Utility of routine pulmonary function test after autologous hematopoietic cell transplantation in lymphomaParastoo B Dahi, Sheila Kenny, Jessica Flynn, et al.
Journal for Immunotherapy of Cancer|February 9, 2025
Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registryDaniel J Landsburg, Matthew J Frigault, Michael Heim, et al.
Nature Medicine|July 3, 2023
CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim resultsJae H Park, Karthik Nath, Sean M Devlin, et al.
Pageof 6

Showing results (21-30 of 53) with videos related to

Sort By:
Pageof 6
British Journal of Haematology|March 6, 2020
Early experience using salvage radiotherapy for relapsed/refractory non-Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T cell therapyBrandon S Imber, Michel Sadelain, Carl DeSelm, et al.
Transplantation and Cellular Therapy|October 3, 2023
Reduced-Intensity Compared to Nonmyeloablative Conditioning in Patients with Non-Hodgkin Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell TransplantationKarthik Nath, Kristen Peterson, Samantha Brown, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 18, 2025
Dermatologic Adverse Events Following CD19-Directed CAR T-Cell Therapy in Hematologic MalignanciesRyan Storgard, Rachel E Reingold, Rose Parisi, et al.
JACC. Cardiooncology|February 18, 2026
Atrial Fibrillation Following Autologous Stem Cell Transplantation in Multiple Myeloma: Incidence, Predictors, and Prognostic ImpactOlayiwola Bolaji, Samantha Brown, Brian C Shaffer, et al.
Haematologica|August 18, 2025
Two decades of single-institution data reveal rare long-term survivors of relapsed/refractory Burkitt lymphomaRabeya Molla, Kurt Bantilan, Ellin Berman, et al.
Haematologica|June 22, 2023
Predictors of SARS-CoV-2 Omicron breakthrough infection after receipt of AZD7442 (tixagevimab-cilgavimab) for pre-exposure prophylaxis among hematologic malignancy patientsJustin C Laracy, Judy Yan, Samantha N Steiger, et al.
Research Square|March 3, 2023
Bortezomib, Lenalidomide and Dexamethasone (VRd) vs Carfilzomib, Lenalidomide and Dexamethasone (KRd) as Induction Therapy in Newly Diagnosed Multiple MyelomaCarlyn Rose Tan, Andriy Derkach, David Nemirovsky, et al.
Leukemia & Lymphoma|September 10, 2023
Utility of routine pulmonary function test after autologous hematopoietic cell transplantation in lymphomaParastoo B Dahi, Sheila Kenny, Jessica Flynn, et al.
Journal for Immunotherapy of Cancer|February 9, 2025
Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registryDaniel J Landsburg, Matthew J Frigault, Michael Heim, et al.
Nature Medicine|July 3, 2023
CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim resultsJae H Park, Karthik Nath, Sean M Devlin, et al.
Pageof 6